Advertisement
Advertisement
September 18, 2026
Piraeus Medical Launches FDA-Cleared 6-F 70 NeuGlide Catheter
KEY TAKEAWAYS
- Piraeus Medical announced the United States launch and first clinical cases of its FDA-cleared 6-F 70 NeuGlide catheter.
- The catheter is indicated for introducing interventional devices into the peripheral, coronary, and neuro vasculature.
- Waleed Brinjikji, MD, commented on one of the first uses with the device in a complex dural arteriovenous fistula procedure through 6-F access.
September 18, 2026—Piraeus Medical, Inc. announced the United States launch and first clinical cases of the company’s 6-F 70 NeuGlide catheter, which has received FDA clearance.
The company stated that the 6-F 70 NeuGlide joins the 7-F 87 NeuGlide+ and 8-F 93 NeuFlex catheters in Piraeus’s neurointerventional access portfolio. The three devices are indicated for the introduction of interventional devices into the peripheral, coronary, and neuro vasculature.
According to Piraeus Medical, the 6-F 70 NeuGlide is built on the company’s linerless catheter construction. It is engineered to optimize inner diameter relative to outer diameter while combining distal flexibility with proximal support.
After performing one of the first United States procedures with the 6-F 70 NeuGlide, Waleed Brinjikji, MD, commented in the company’s press release, “It was an honor to perform the first-in-human case with the new 6-F NeuGlide from Piraeus. I haven’t seen anything like it. The proximal support and distal flexibility of the catheter allowed us to achieve the distal positioning necessary to successfully take down a complex dural arteriovenous fistula, all through 6F access.”
Advertisement
Advertisement
